MISSION Therapeutics Strengthens Board
News Oct 01, 2012
MISSION Therapeutics has announced the appointment of Dr Michael Moore as Executive Chairman and Fritz Frickel as Non-Executive Director.
Graziano Seghezzi of Sofinnova partners, on behalf of the investor syndicate, commented: “We warmly welcome Michael Moore and Fritz Frickel to the MISSION Board. Their combined commercial, drug translational and managerial experience will complement our existing capabilities and provide valuable links with the pharma and venture capital industries with which they have both enjoyed highly productive relationships”.
Dr Moore brings extensive experience to MISSION at a formative phase of the company’s development.
Following an earlier academic career principally at the Paterson Institute for Cancer Research (University of Manchester), Dr Moore has more than two decades of senior management experience in the biotechnology sector, as Chief Scientific Officer of Xenova Group plc and more recently as Chief Executive Officer of Piramed, the UK bioscience company acquired by F Hoffmann-La Roche in 2008.
Dr Moore also serves as a Non-Executive Director of several companies including PsiOxus Therapeutics. He is also a member of the Cancer Research UK Science Committee.
Dr Fritz Frickel joins the MISSION Board as a non-executive director. Currently an independent advisor to venture capital firms, biotech start-ups and universities, Dr Frickel was formerly Senior Vice-President of R&D and acting CEO of Alantos which was acquired by Amgen.
Other senior pharma roles have included SVP of research at Abbott, world-wide head of research at BASF and head of clinical, pharmaceutical and regulatory development at Knoll.
Dr Frickel served as non-executive director of RespiVert, an Imperial College spin-out, until its acquisition by Janssen Biotech Inc. in 2010 and is currently a director of new start-up company TopiVert.
Glythera Appoints Chief Scientific Officer and Strengthens SABNews
Dr Robert Lutz appointed as CSO to support development of next-generation PermaLink® Antibody Drug Conjugates. Dr Jon Roffey appointed to Scientific Advisory Board.READ MORE
Missing Hormone Gene Linked to Incurable Prostate CancerNews
A study has shown that the loss of a subtype of the gene HSD17B4 can contribute to treatment-resistant prostate cancer.READ MORE